Birla Estates, a wholly owned subsidiary of Aditya Birla Real Estate (ABREL), has achieved bookings exceeding Rs 1,600 crore for its luxury project, Birla Arika Phase 2 in Sector 31, Gurugram. Nearly 97% of the residences-152 of 156 units-were sold within a month of launch, underlining strong buyer confidence in the brand's luxury developments in Gurugram.
Birla Arika is a luxury residential development strategically located in Central Gurugram, one of the city's most established and well-connected residential micro-markets. The strong performance of Phase 2 reflects a broader shift in buyer preferences toward spacious residences, expansive landscaped areas, and thoughtfully curated lifestyle amenities aligned with evolving urban living aspirations. Envisioned as a low-density community, the project features four exclusive clubs, each offering distinct and immersive lifestyle experiences tailored to diverse resident needs.
Alembic Pharmaceuticals (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Dapagliflozin Tablets, 5 mg and 10 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Farxiga Tablets, 5 mg and 10 mg, of AstraZeneca AB (AstraZeneca). Dapagliflozin tablet is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated: i) to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors, and ii) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Alembic was one of the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification for Dapagliflozin Tablets, 5 mg and 10 mg. Therefore, with this approval, Alembic is eligible for 180 days of shared generic drug exclusivity.
Dapagliflozin tablets, 5 mg and 10 mg, have an estimated market size of US$ 10,487 million for twelve months ending December 2025 according to IQVIA.
Alkem Laboratories announced the launch of A to Z Daily, an everyday multivitamin supplement for adults, for providing holistic nutritional support to the body and mind.
A to Z Daily tablets are formulated with a total of 26 essential vitamins, minerals and botanicals to provide balanced nutritional support. The key vitamins and minerals include Vitamin B complex, Vitamin D3, Vitamin C, Zinc, and Iron that help in boosting energy levels, reducing fatigue and improving immunity. The product also contains clinically researched botanicals such as Ashwagandha, Bacopa monnieri (Brahmi), Panax ginseng, and an amino acid L-theanine, which help in managing stress and anxiety, improving sleep quality and supporting the cognitive function.
Commenting on the launch, Dr. Vikas Gupta, Chief Executive Officer, Alkem, said, “Our current lifestyles are placing sustained demands not just on physical health but also on mental well-being. People are increasingly experiencing stress, fatigue, and reduced ability to stay focused. Nutritional supplementation can play a supportive role in addressing these challenges when designed thoughtfully. A to Z Daily brings together essential ingredients to provide a balanced, everyday support for both body and mind. It is positioned not as a quick fix, but as a consistent, long-term approach for people seeking to manage everyday stress while improving overall vitality.”
Arvind SmartSpaces announced the signing of a residential high-rise project in Goregaon (West), Mumbai. The project has a top-line potential of ~Rs. 2,400 crore , with a total saleable carpet area of ~0.67 million sq. ft. The project is being done in partnership with Sigma Oxford Realtors. The Company will jointly do a redevelopment in Siddharth Nagar, Goregaon West, one of the most sought-after micro markets in Mumbai's Western suburbs.
This project marks the Company's third housing project in MMR and its second high-rise project in the city, further strengthening its presence in the Mumbai Metropolitan Region (MMR).
These products will be manufactured at Unit-IV of APL Healthcare, a wholly owned subsidiary of the Company and will be launched immediately.